64187-48-0

Basic information

• Product Name: Z-HYP-OME
• Synonyms: N-Cbz-trans-4-hydroxy-L-proline methyl ester;Z-O-tert-Butyl-L-4-hydroxyproline;(2S,4R)-1-(Benzyloxycarbonyl)-2-(methoxycarbonyl)-4-hydroxypyrrolidine;(2S,4R)-1-Benzyloxycarbonyl-4-hydroxypyrrolidin-2-carboxylic acid methyl ester;1-Benzyl 2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate;N-(Benzyloxycarbonyl)-4-hydroxyproline methyl ester;(2S,4R)-1-benzyl 2-Methyl 4-hydro×ypyrrolidine-1,2-dicarbo×ylate;N-Benzyloxycarbonyl-4-trans-hydroxy-L-proline Methyl ester, 98%
• CAS NO: 64187-48-0
• Molecular Formula: C₁₄H₁₇NO₅
• Molecular Weight: 279.29
• EINECS: 236-831-2
• Mol File: 64187-48-0.mol

Chemical Properties

• Boiling Point: 422.779 °C at 760 mmHg
• Flash Point: 209.49 °C
• Appearance: Pale yellow/viscous liquid
• Density: 1.313
• Vapor Pressure: 6.67E-08mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: −20°C
• PKA: 14.25±0.40(Predicted)
• CAS DataBase Reference: Z-HYP-OME(CAS DataBase Reference)
• NIST Chemistry Reference: Z-HYP-OME(64187-48-0)
• EPA Substance Registry System: Z-HYP-OME(64187-48-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 64187-48-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Z-HYP-OME is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to facilitate the creation of new drugs and therapies.
Used in Antibacterial Applications:
Z-HYP-OME is used in the synthesis of Doripenem (D534800), an antibacterial agent, for its contribution to the development of effective treatments against bacterial infections.

InChI:InChI=1/C14H17NO5/c1-19-13(17)12-7-11(16)8-15(12)14(18)20-9-10-5-3-2-4-6-10/h2-6,11-12,16H,7-9H2,1H3/t11-,12+/m1/s1

Upstream product

• 62210-73-5 N-<<(benzyloxy)carbonyl>oxy>-5-norbornene-2,3-dicarboximide 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 124-41-4 sodium methylate 
• 13500-53-3 N-benzyloxycarbonyl-(2S,4R)-4-hydroxyproline benzyl ester 
• 186581-53-3 diazomethane 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 67-56-1 methanol 
• 501-53-1 benzyl chloroformate 
• 74-88-4 methyl iodide 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 
• 51-35-4 4R-4-hydroxyproline 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 

Downstream Products

• 126111-26-0 trans-4-(2,2-dimethyl-1-oxopropoxy)-1-<(phenylmethoxy)carbonyl>-L-proline methyl ester 
• 146952-00-3 (2S,4R)-1-(Benzyloxycarbonyl)-4--2-pyrrolidincarbonsaeure-methylester 
• 114358-14-4 O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate 
• 128359-96-6 (2S,4S)-4-acetoxy-1,2-pyrrolidinedicarboxylic acid 2-methyl 1-phenylmethyl diester 
• 117811-78-6 methyl (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylate 
• 115545-74-9 Cbz-4-(2-cyanoethyl)-Pro-OMe 
• 57653-38-0 N-<(phenylmethoxy)carbonyl>-4(R)-<<(4-methylphenyl)sulfonyl>oxy>-(S)-proline methyl ester 
• 146951-99-7 (2S,4R)-1-(Benzyloxycarbonyl)-4-(tert-butyloxy)-2-pyrrolidincarbonsaeure-methylester 
• 72180-14-4 N-<(phenylmethoxy)carbonyl>-4(S)-fluoro-(S)-proline methyl ester 
• 122350-62-3 (2S,4R)-4-((2R,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 122350-62-3 (2S,4R)-4-((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 

Relevant articles and documents

Practical Gram-Scale Synthesis of Iboxamycin, a Potent Antibiotic Candidate

A gram-scale synthesis of iboxamycin, an antibiotic candidate bearing a fused bicyclic amino acid residue, is presented. A pivotal transformation in the route involves an intramolecular hydrosilylation-oxidation sequence to set the ring-fusion stereocenters of the bicyclic scaffold. Other notable features of the synthesis include a high-yielding, highly diastereoselective alkylation of a pseudoephenamine amide, a convergent sp3-sp2 Negishi coupling, and a one-pot transacetalization-reduction reaction to form the target compound's oxepane ring. Implementation of this synthetic strategy has provided ample quantities of iboxamycin to allow for its in vivo profiling in murine models of infection.

NOVEL SALT OF 4-({(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4(METHYLSULFONYL)PIPERAZIN-1-YL]-L-PROLYL}AMINO) BENZOIC ACID AND NOVEL CRYSTAL FORM THEREOF

4-({(4S)-1-(4-Carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-L-prolyl}amino) benzoic acid di(4-toluenesulfonate) or dibenzenesulfonate or their crystal forms can be useful pharmaceutical ingredients because of their low hygroscopicity and excellent storage stability.

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

Asymmetric 1,4-Michael Addition in Aqueous Medium Using Hydrophobic Chiral Organocatalysts

Organic transformations exclusively in water as an environmentally friendly and safe medium have drawn significant interest in the recent years. Moreover, transition metal-free synthesis of enantiopure molecules in water will have a great deal of attentio

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

Synthesis of γ-Hydroxy-α-amino Acid Derivatives by Enzymatic Tandem Aldol Addition-Transamination Reactions

Three enzymatic routes toward γ-hydroxy-α-amino acids by tandem aldol addition-transamination one-pot two-step reactions are reported. The approaches feature an enantioselective aldol addition of pyruvate to various nonaromatic aldehydes catalyzed by trans-o-hydroxybenzylidene pyruvate hydratase-aldolase (HBPA) from Pseudomonas putida. This affords chiral 4-hydroxy-2-oxo acids, which were subsequently enantioselectively aminated using S-selective transaminases. Three transamination processes were investigated involving different amine donors and transaminases: (i) l-Ala as an amine donor with pyruvate recycling, (ii) a benzylamine donor using benzaldehyde lyase from Pseudomonas fluorescens Biovar I (BAL) to transform the benzaldehyde formed into benzoin, minimizing equilibrium limitations, and (iii) l-Glu as an amine donor with a double cascade comprising branched-chain α-amino acid aminotransferase (BCAT) and aspartate amino transferase (AspAT), both from E. coli, using l-Asp as a substrate to regenerate l-Glu. The γ-hydroxy-α-amino acids thus obtained were transformed into chiral α-amino-γ-butyrolactones, structural motifs found in many biologically active compounds and valuable intermediates for the synthesis of pharmaceutical agents.

FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

NOVEL BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.